Literature DB >> 28274032

Disseminated Intravascular Coagulation and Excessive Fibrinolysis (DIC XFL) Syndrome in Prostate Cancer: A Rare Complicated Disorder.

Azhar Bin Amir Hamzah1, Yew Maw Choo2, Mohamed Azmi Hassali3, Fahad Saleem4, Ashutosh Kumar Verma5.   

Abstract

Disseminated Intravascular Coagulation (DIC) develops in patient with prostate cancer, which is manifested by systemic, intracranial, intracavitary or intracutaneous bleeding indicating uncompensated or excessive fibrinolysis (XFL). This case report is a description of a 61-year-old male with metastatic prostate cancer that progressed to manifest DIC. The condition is rare in clinical practice, and even rarer when is coupled with XFL. Treatment was mainly replenishing coagulation factors, platelets and controlling the disease progression with aggressive hormonal therapy. The patient progressed to coagulopathy further with fibrinolysis, hence leading to mortality. This case study discusses the pathophysiology of this complication and various methods to monitor the disease progression are discussed.

Entities:  

Keywords:  Fibrinolysis; Hormonal therapy; Intravascular Coagulation; Metastatic prostate cancer

Year:  2017        PMID: 28274032      PMCID: PMC5324477          DOI: 10.7860/JCDR/2017/22582.9313

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

Review 1.  Complications of advanced prostate cancer.

Authors:  J A Smith; M S Soloway; M J Young
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

Review 2.  Coagulopathy in prostate cancer.

Authors:  C de la Fouchardière; A Flechon; J P Droz
Journal:  Neth J Med       Date:  2003-11       Impact factor: 1.422

3.  [Haematological complications of prostatic cancer: 2 cases, one revealing the neoplasia].

Authors:  L Albiges; P-H Cottu; I Cojean-Zelek; F Raymond; D Zerkak; J Aerts; J-M Ziza
Journal:  Rev Med Interne       Date:  2007-01-03       Impact factor: 0.728

4.  Prostate cancer: beware of disseminated intravascular coagulation.

Authors:  Mihir Desai; Babbin John; Gillian Evans; Ben Eddy
Journal:  BMJ Case Rep       Date:  2015-03-27

Review 5.  Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature.

Authors:  David M Hyman; Gerald A Soff; Lewis J Kampel
Journal:  Oncology       Date:  2011-10-06       Impact factor: 2.935

6.  Carcinoma of the prostate presenting as acute disseminated intravascular coagulation.

Authors:  J I Spector; H Zimbler
Journal:  CMAJ       Date:  1987-03-15       Impact factor: 8.262

7.  Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer.

Authors:  Ignacio Duran; Ian F Tannock
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

8.  Hypofractionated radiotherapy as local hemostatic agent in advanced cancer.

Authors:  Malik Tariq Rasool; Najmi Arshad Manzoor; Syed Arshad Mustafa; Lone Mohammad Maqbool; Fir Afroz
Journal:  Indian J Palliat Care       Date:  2011-09

9.  Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report.

Authors:  Yoshihiro Wada; Mitsuhiro Uchiba; Yoshiaki Kawano; Nobuyuki Kai; Wataru Takahashi; Jiro Honda; Ken-Ichiro Tanoue; Yoshihiro Maeda; Yoji Murakami; Masatoshi Eto; Takahisa Imamura
Journal:  J Med Case Rep       Date:  2012-11-06
  9 in total
  3 in total

1.  D-dimer as a potential clinical marker for predicting metastasis and progression in cancer.

Authors:  Hong Dai; Hongxing Zhou; Yingxin Sun; Zhe Xu; Shuo Wang; Tongbao Feng; Ping Zhang
Journal:  Biomed Rep       Date:  2018-09-14

2.  Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.

Authors:  Frank Sheng Fan; Chung-Fan Yang
Journal:  Clin Pract       Date:  2019-05-06

Review 3.  D-Dimer: A Potential Solution to Problems of Cancer Screening, Surveillance, and Prognosis Assessment.

Authors:  Nabeel A Siddiqui; Mushrin Malik; Ransirini Wijeratne Fernando; Archana Sreekantan Nair; Janan Illango; Rajvi Gor; Pousette Hamid
Journal:  Cureus       Date:  2021-05-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.